Anixa Biosciences, Inc. (NASDAQ:ANIX) Sees Significant Increase in Short Interest

Anixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) was the target of a significant increase in short interest in the month of January. As of January 31st, there was short interest totalling 403,100 shares, an increase of 13.7% from the January 15th total of 354,500 shares. Currently, 1.3% of the company's shares are short sold. Based on an average daily trading volume, of 121,000 shares, the short-interest ratio is currently 3.3 days.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on ANIX shares. D. Boral Capital reiterated a "buy" rating and issued a $10.00 price objective on shares of Anixa Biosciences in a research note on Wednesday, January 22nd. HC Wainwright reiterated a "buy" rating and issued a $7.00 price target on shares of Anixa Biosciences in a research note on Tuesday, November 19th.

Anixa Biosciences Stock Performance

NASDAQ ANIX traded down $0.10 during trading on Tuesday, reaching $3.05. 42,613 shares of the company's stock were exchanged, compared to its average volume of 120,491. The stock has a market cap of $98.05 million, a P/E ratio of -7.78 and a beta of 0.93. The company has a 50 day moving average price of $2.70 and a two-hundred day moving average price of $3.05. Anixa Biosciences has a 1 year low of $2.07 and a 1 year high of $4.20.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last posted its earnings results on Friday, January 10th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.02. Research analysts forecast that Anixa Biosciences will post -0.46 EPS for the current fiscal year.

Insider Transactions at Anixa Biosciences

In other Anixa Biosciences news, Director Lewis H. Titterton, Jr. acquired 10,000 shares of the stock in a transaction dated Friday, January 17th. The stock was acquired at an average price of $2.57 per share, with a total value of $25,700.00. Following the completion of the purchase, the director now owns 922,334 shares in the company, valued at $2,370,398.38. This trade represents a 1.10 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Amit Kumar purchased 43,000 shares of the firm's stock in a transaction on Wednesday, January 15th. The stock was acquired at an average cost of $2.23 per share, with a total value of $95,890.00. Following the transaction, the chief executive officer now directly owns 559,925 shares in the company, valued at $1,248,632.75. This trade represents a 8.32 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought a total of 75,289 shares of company stock worth $177,021 over the last ninety days. Company insiders own 22.60% of the company's stock.

Institutional Trading of Anixa Biosciences

Several institutional investors have recently modified their holdings of ANIX. Millennium Management LLC purchased a new stake in Anixa Biosciences in the fourth quarter valued at $26,000. Virtu Financial LLC purchased a new stake in shares of Anixa Biosciences in the 3rd quarter valued at about $34,000. Renaissance Technologies LLC lifted its holdings in shares of Anixa Biosciences by 36.5% in the 4th quarter. Renaissance Technologies LLC now owns 14,573 shares of the company's stock valued at $34,000 after purchasing an additional 3,900 shares during the last quarter. Prosperity Wealth Management Inc. purchased a new stake in shares of Anixa Biosciences in the 4th quarter valued at about $54,000. Finally, Jane Street Group LLC purchased a new stake in shares of Anixa Biosciences in the 4th quarter valued at about $67,000. Hedge funds and other institutional investors own 29.13% of the company's stock.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.